| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Adamts13 ELISA kit; Gm710A disintegrin and metalloproteinase with thrombospondin motifs 13 ELISA kit; ADAM-TS 13 ELISA kit; ADAM-TS13 ELISA kit; ADAMTS-13 ELISA kit; EC 3.4.24.87 ELISA kit; von Willebrand factor-cleaving protease ELISA kit; vWF-CP ELISA kit; vWF-cleaving protease ELISA kit |
| Assay Time | |
| Assay Type | |
| Detection Range | |
| Detection Wavelength | |
| Product Type | |
| Reactivity | |
| Sample Type(s) | serum, plasma, tissue homogenates |
| Sensitivity | |
| Species | |
| Target | |
| UniProt # |
Background
ADAM metallopeptidase with thrombospondin type 1 motif, 13 (ADAMTS13) is a biological molecule commonly studied in cancer research. It is commonly used as a molecular readout in mechanistic and biomarker-focused studies.
UniProt: Q769J6
Biological context
Researchers often monitor ADAM metallopeptidase with thrombospondin type 1 motif, 13 (ADAMTS13) in serum, plasma, and tissue homogenates to better understand themes such as tumor microenvironment biology, cell proliferation and apoptosis, and metastasis and invasion pathways. In many model systems, measured levels can shift with physiology, experimental perturbation, or disease-associated changes, making careful biological interpretation important.
Interpreting changes in measured levels
Depending on sample matrix and study design, increases or decreases in ADAM metallopeptidase with thrombospondin type 1 motif, 13 (ADAMTS13) may reflect differences in expression, secretion, turnover, or compartmentalization rather than a single mechanism. Interpretation is typically strengthened by evaluating related molecules (for example, cell-cycle regulators, invasion/ECM markers, and immune-oncology mediators) and by keeping pre-analytical variables consistent across groups.
Nomenclature
In publications and databases, ADAM metallopeptidase with thrombospondin type 1 motif, 13 (ADAMTS13) may also appear under names such as Adamts13 and Gm710A disintegrin and metalloproteinase with thrombospondin motifs 13. When comparing studies, confirm that the reported analyte refers to the same molecule and species context.
Why ELISA data are widely used
ELISA is a common approach for quantitative measurement of proteins and biomarkers in complex samples, enabling comparisons across experimental groups and time points. When integrating results with other readouts, consider species biology, sample type, and the broader pathway context that ADAM metallopeptidase with thrombospondin type 1 motif, 13 (ADAMTS13) participates in.
Can’t Find What You’re Looking For? We can help you source the best match or customize an ELISA solution for your study. Options may include alternative target synonyms, different species reactivity, sample type/matrix compatibility (serum/plasma/lysate/supernatant), assay format (sandwich/competitive), sensitivity/range, detection chemistry (colorimetric/fluorescent/chemiluminescent), plate format (pre-coated/uncoated, strips vs full plate), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
ADAMTS13 attenuates renal fibrosis by suppressing thrombospondin 1 mediated TGF-β1/Smad3 activation
J Guo, S Zhou, H Wang, X Qiu, F Dong, S Jiang,Toxicology and Applied Pharmacology,2025
Von Willebrand factor exacerbates heart failure through formation of neutrophil extracellular traps
G Mang, J Chen, P Sun, R Ma, J Du,European Heart Journal,2024
Isaridin E Protects against Sepsis by Inhibiting Von Willebrand Factor-Induced Endothelial Hyperpermeability and Platelet–Endothelium Interaction
YS Liu,Marine drugs,2024
Cathepsin K deficiency prevented stress-related thrombosis in a mouse FeCl3 model
X Jin,Cellular and molecular life sciences,2024
Von Willebrand factor promotes radiation-induced intestinal injury (RIII) development and its cleavage enzyme rhADAMTS13 protects against RIII by reducing inflammation and oxidative stress
J Xu,Free radical biology & medicine,2023